OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 44,600 shares of the company’s stock, valued at approximately $855,000.

Other large investors have also made changes to their positions in the company. Voya Investment Management LLC boosted its holdings in Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after purchasing an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Viridian Therapeutics by 3.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after buying an additional 1,106 shares during the period. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics in the fourth quarter worth about $26,000. Summit Investment Advisors Inc. grew its holdings in Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after acquiring an additional 1,516 shares during the period. Finally, AlphaQuest LLC raised its position in Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares in the last quarter.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $12.81 on Wednesday. The stock has a market capitalization of $1.05 billion, a P/E ratio of -2.97 and a beta of 0.57. The company’s fifty day moving average price is $13.60 and its 200 day moving average price is $17.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm’s revenue was up .0% on a year-over-year basis. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRDN has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. The Goldman Sachs Group decreased their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. JMP Securities lowered their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada dropped their price target on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, Needham & Company LLC decreased their price objective on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.